Simvastatin has been demonstrated to reduce vascular endothelial growth factor (VEGF) secretion – among other angiogenic growth factors – and inhibit angiogenesis in breast and colon cancer cells (Cho et al. 2008, Li et al. 2017, Wang et al. 2018). Here, VEGFA is linked to malignant colon neoplasm.